International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Criteria for the Diagnosis of Extranodal Extension Detected on Radiological Imaging in Head and Neck Cancer: HNCIG International Consensus Recommendations
Pathological evidence of extranodal extension (pENE) is known to be a negative prognostic factor in head and neck cancer (HNC). The available evidence suggests that radiologically or imaging-detected extranodal extension (iENE) is also associated with worse clinical outcomes. Although the reliable detection of iENE before initiation of treatment may help guide treatment selection, the diagnostic criteria and terminology used to report iENE are not widely agreed upon. The Head and Neck Cancer International Group (HNCIG) conducted a Delphi survey with the aim of developing a framework for decision-making on the most importan...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C. Henson, A. Abou-Foul, C. Glastonbury, S.H. Huang, A. King, W. Lydiatt, L.J. McDowell, A.A. Nagelschneider, P. Nankivell, B. O'Sullivan, R. Rhys, Y. Xiao, E. Yu, S.S. Yom, H. Mehanna Tags: 18 Source Type: research

Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx
The increased incidence of HPV-related cancers has motivated efforts to optimize treatment paradigms for these excellent-prognosis patients. Validation of surrogates for overall survival (OS) could expedite the evaluation of new therapies. We sought to validate candidate intermediate clinical endpoints (ICE) in trials assessing definitive treatment of p16-positive oropharyngeal cancer with (chemo)radiation. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L.A. Gharzai, E. Morris, P.F. Nguyen-Tan, D.I. Rosenthal, M. Gillison, P.M. Harari, A.S. Garden, K. Zanotti, J.J. Caudell, C.U. Jones, D.L. Mitchell, G.A. Krempl, J.A. Ridge, M.F. Gensheimer, J.A. Bonner, Q.T. Le, P. Torres-Saavedra, M.L. Mierzwa, M. Schi Tags: 100 Source Type: research

Radiotherapy for Older Patients with Oropharyngeal Cancer
Previous research has estimated that the optimal radiotherapy utilisation (RTU) rate for patients with head and neck cancer is 74%. However, there is limited data on the actual RTU rate for older patients with head and neck cancer and in particular, older patients with oropharyngeal cancer. The aims of this research were to determine the actual RTU rate, radiotherapy dose, comorbidity, and survival rate according to age group for patients with oropharyngeal cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: P. Mackenzie, V. Donoghue, D. Cossico, T. Guan, B. Burmeister Tags: 101 Source Type: research

Feasibility of Adaptive Radiation Therapy for Human-Papilloma Virus-Positive Oropharyngeal Cancer Patients Using MR-Guided RT
Human-papilloma virus (HPV)-positive oropharyngeal cancer (OPC) is a potentially curable disease with a rising incidence in the United States. Despite improved radiation therapy (RT) techniques, toxicities remain a concern. Adaptive RT (ART) can reduce radiation to organs-at-risk (OARs) without sacrificing tumoricidal dose to target volumes, but there are barriers to routine implementation. These include (1) technical barriers to ART and (2) timing of ART for shrinking tumor volumes or changes in body contours (such as weight loss or contracture of OARs). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Jethanandani, L.M. Freedman, G.J. Kubicek, M.C. Abramowitz, G.A. Azzam, B.J. Rich, W. Jin, S. Samuels Tags: 102 Source Type: research

Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
HPV-driven oropharyngeal squamous cell cancer (OPSCC) has a high cure rate and a high burden of treatment-related toxicities. Transoral robotic surgery (TORS) is a treatment option for patients with early-stage disease. Most patients will be recommended adjuvant RT. ECOG 3311 was a phase 2 trial demonstrating that patients with intermediate pathologic risk factors treated with 50 Gy of adjuvant RT had similar survival as those receiving the current standard 60 Gy of adjuvant RT. However, 50 Gy is still associated with meaningful toxicity, specifically with respect to impaired swallowing function. (Source: International Jou...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.E. Bates, W.A. Stokes, M.W. McDonald, S. Rudra, J.S. Remick, M.M. Stallings, N.F. Saba, N.C. Schmitt, J.H. Gross, A.S. Kaka, M.R. Patel Tags: 103 Source Type: research

Adjusted RECIST Criteria for Assessing Time to Recurrence in Patients with Fully Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
RECIST criteria to assess response and progression in solid tumors were published in 2000 and updated to Version 1.1 in 2009. For patients with resected SCCHN and without macroscopic residual disease, no imaging-based criteria exist for the multidisciplinary team to jointly assess time to recurrence, and many components of RECIST 1.1 do not apply (eg, baseline target and nontarget lesions). However, some aspects of RECIST 1.1 criteria are applicable, including size increase thresholds for relapses in lymph nodes, indicating RECIST disease progression in patients without imaging-assessed macroscopic disease at baseline. (So...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S.P. Eggleton, M. O'Neal, R. Ford, A. Schroeder, M. Bajars, C. Le Tourneau, R.L. Ferris Tags: 104 Source Type: research

Comparison of Induction Cisplatin, Docetaxel, and 5-Fluorouracil to An Induction Platinum Doublet Regimen for Locally Advanced Human Papillomavirus-Associated Oropharyngeal Cancer
Management of locoregionally advanced (LA) human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) often entails induction chemotherapy (IC) followed by definitive chemoradiation. The standard IC regimen for head and neck cancer, docetaxel, cisplatin, and 5-fluorouracil (TPF), has a high rate of toxicity. Due to the chemosensitivity of HPV(+)OPSCC, platinum-taxane doublets are often used as IC with less toxicity. No study to date has compared TPF to a platinum-taxane doublet IC regimen. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Ganti, P.W. McGarrah, H. Fuentes Bayne, C. Fazer-Posorske, D.J. Ma, S.C. Lester, D.M. Routman, M.A. Neben-Wittich, M.E. Gamez, J.M. Wilson, D.L. Price, E.J. Moore, K.K. Tasche, K.M. Van Abel, L.X. Yin, N.R. Foster, K. Price Tags: 105 Source Type: research

Clinical Outcomes of Human papillomavirus (HPV) Testing Discordance in Oropharyngeal Squamous cell Carcinoma
In this study, we analyzed the discordance between p16 IHC and HPV status in patients treated with definitive (chemo)radiation (CRT) for OPSCC and any potential association with treatment outcome. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.F. Shenker, J. Saifullan, J. Canick, X. Jiang, Z. Wan, D. Niedzwiecki, R.T. Hughes, Y.M. Mowery, D.M. Brizel Tags: 106 Source Type: research

XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)
The current standard of care for patients (pts) with resected LA SCCHN who are at high-risk of disease recurrence and are cisplatin eligible is chemoradiotherapy (CRT; cisplatin  + RT). For pts who cannot receive cisplatin, treatment options are limited, and there is currently no treatment specifically recommended by international guidelines. Xevinapant, a first-in-class, small-molecule inhibitor of apoptosis protein inhibitor, has been shown to restore cancer cell sens itivity to apoptosis, thereby enhancing the effects of chemotherapy and RT. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.L. Ferris, H. Mehanna, J.D. Schoenfeld, M. Tahara, S.S. Yom, R.I. Haddad, A. K önig, S. Salmio, M. Bajars, C. Le Tourneau Tags: 107 Source Type: research

Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202
The prognosis of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (SCC) is poor (median overall survival [OS] 10 –13 mo), and effective treatments are needed. The cell-adhesion molecule Nectin-4 is expressed in a majority of HNCs. EV is a Nectin-4–directed antibody–drug conjugate approved as monotherapy in previously treated locally advanced or metastatic (la/m) urothelial carcinoma (UC) and, in the US, with pembrolizumab for previously untreated la/mUC ineligible for cisplatin. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: P.L. Swiecicki, E. Yilmaz, A.J. Rosenberg, T. Fujisawa, J.Y. Bruce, C. Meng, M.A. Wozniak, L. Wang, S. Gorla, J.L. Geiger Tags: 108 Source Type: research

Systematic Implementation of Effective Quality Assurance Processes for the Assessment of Radiation Target Volumes in Head and Neck Cancer
This study aims to assess the effectiveness of implementing prospective peer-review into practice for our National Cancer Institute-Designated Cancer Center and to report factors associated with contour modifications. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D.N. Schaefer, A. Ewing, T.Y. Andraos, D.J. DiCostanzo, M. Weldon, D. Christ, S. Baliga, S.R. Jhawar, D.L. Mitchell, J.C. Grecula, D.J. Konieczkowski, J.D. Palmer, T. Jahraus, K. Dibs, A. Chakravarti, D.D. Martin, M.E. Gamez, D.M. Blakaj, E. Gogineni Tags: 109 Source Type: research

Oncological Outcomes of Partial thickness Calvarial Resection for Locally Advanced Scalp Malignancies
This study aims to provide a comprehensive examination of its clinical applications and the postoperative oncological outcomes it yields. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S. Farsi, R. Gardner, D. King, J. Sunde, E. Vural, M. Moreno, J.Q. Odom Tags: 110 Source Type: research

One Year Experience of a Radiation Oncology Semi-weekly Head & Neck Contour Peer Review at a Single Institution
Because head and neck radiotherapy is complex, relying solely on a weekly chart review is inadequate for evaluating radiation oncology contours. Implementing a dedicated semi-weekly examination of all head and neck contours prior to radiation treatment planning, allowing for comprehensive assessment of images and treatment targets, may result in improved patient outcomes. Conducting a thorough assessment of all head and neck contours also exposes resident physicians to a greater volume of patient contours for education purposes. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.J. Megahed, S. Samanta, M. Patel, A. Wurtz, A.Z. Kesaria, K. Wang, P.D. McClain, G.D. Lewis Tags: 111 Source Type: research

Comparison of TTMV-HPV DNA to Gold Standard PET for Evaluation of Treatment Response in HPV-Associated Oropharyngeal Cancer after Definitive Treatment
The rise in oropharyngeal squamous cell carcinoma (OPSCC) is being driven by human papillomavirus (HPV)-associated disease. The standard of care in diagnosis and surveillance is tissue diagnosis guided by imaging, especially in the non-surgical treatment. There is interest in utilizing plasma tumor tissue-modified (TTMV)-HPV DNA in diagnosis and surveillance. The goal of the study was to compare (TTMV)-HPV DNA against the gold standard, PET-CT in OPSCC managed with definitive therapy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R. Song, P. Sun Cao, K. Sura Tags: 112 Source Type: research

Induction Chemotherapy for Oropharyngeal Cancer: A Single Institution Retrospective Review
Head and neck cancers place healthy tissues in close proximity to tumor volumes, increasing toxicity risk. Induction chemotherapy (IC) allows pre-chemoradiotherapy cytoreduction. We hypothesized that treating patients with oropharyngeal cancer (OPC) to the post-induction volume would decrease grade 3+ toxicity compared with the pre-induction volume. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C. Geno, D.K. Ebner, M. Neben Witt, S.C. Lester, D.M. Routman, M. Gamez, J.M. Wilson, K. Price, H. Fuentes, P.W. McGarrah, D.J. Ma Tags: 113 Source Type: research